Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Respiratory syncytial virus (RSV) causes symptoms similar to the common cold. But in older adults and those with certain medical conditions, the virus can increase the risk of serious illnesses.

Respiratory syncytial virus (RSV) affects infants, young children, and older adults, particularly those with compromised respiratory or cardiovascular health. Every year RSV causes approximately ...

In comparison to previous periods, a larger fraction of the pediatric population hospitalized due to respiratory syncytial virus infections between 2022 and 2023 was two to five years of age (34% ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Killing on average over 100,000 children across the world per year, respiratory syncytial virus (RSV) is the second greatest cause of death by a single pathogen for children under one year of age ...

Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory tract infections worldwide, recently there has been a surge in interest in RSV antigens, antibodies, and more in ...